NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · IEX Real-Time Price · USD
0.759
-0.010 (-1.24%)
At close: Apr 26, 2024, 4:00 PM
0.760
+0.002 (0.20%)
After-hours: Apr 26, 2024, 5:38 PM EDT
NanoVibronix Revenue
In the year 2023, NanoVibronix had annual revenue of $2.28M with 203.59% growth. Revenue in the quarter ending December 31, 2023 was $1.18M, a -1,253.92% decrease year-over-year.
Revenue (ttm)
$2.28M
Revenue Growth
+203.59%
P/S Ratio
0.92
Revenue / Employee
$228,300
Employees
10
Market Cap
2.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
Dec 31, 2019 | 530.00K | 212.00K | 66.67% |
Dec 31, 2018 | 318.00K | 79.00K | 33.05% |
Dec 31, 2017 | 239.00K | 10.00K | 4.37% |
Dec 31, 2016 | 229.00K | 82.00K | 55.78% |
Dec 31, 2015 | 147.00K | -56.00K | -27.59% |
Dec 31, 2014 | 203.00K | -8.00K | -3.79% |
Dec 31, 2013 | 211.00K | 45.00K | 27.11% |
Dec 31, 2012 | 166.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNAOV News
- 2 days ago - NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 - Accesswire
- 17 days ago - NanoVibronix Issues Letter to Stockholders - Business Wire
- 4 weeks ago - NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield - Business Wire
- 5 months ago - NanoVibronix Featured in Your Bladder Health Magazine - Business Wire
- 5 months ago - NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity - Business Wire
- 5 months ago - NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan - Business Wire
- 5 months ago - NanoVibronix Regains Nasdaq Compliance - Business Wire
- 5 months ago - NanoVibronix Issues Letter to Shareholders - Business Wire